



Press release

Takeda Drives Innovation with New State-of-the-art Biotech Facility in Neuchâtel

- 200 million Swiss Francs is the largest single investment ever made at Takeda's Neuchâtel site
- New building for aseptic filling and extension of existing facility building
- Expansion of rare disease treatment production capabilities

Neuchâtel, Switzerland, November 26, 2025 – Takeda (TSE:4502/NYSE:TAK) will inaugurate a new facility with an aseptic filling line in Neuchâtel, following an investment of more than 200 million Swiss Francs. This is the largest single investment ever made at the site, aimed at enhancing its production capacity to better address unmet medical needs and expand access to treatments for patients living with rare diseases such as bleeding disorders. The inauguration ceremony, which will be attended by Swiss and Japanese political representatives, underscores Takeda's strategic role in both the cantonal and Swiss economy and the global biotechnology landscape.

A new cutting-edge production line

The new aseptic filling line includes formulation, filling, freeze-drying, capping and automated visual inspection. It will strengthen the site's ability to deliver live-transforming treatments for rare diseases to patients in more than 80 countries. The project is part of the site's digital transformation and the development of a "factory of the future," where automation and digitalization play a central role.

"This investment reflects our commitment to strengthening Takeda's global biopharmaceutical manufacturing capacity by integrating the most advanced digital and automated technologies. With this new infrastructure, we will be able to serve more patients with rare diseases, while contributing to the economic and industrial vitality of the region," said Thomas Wozniowski, Global Manufacturing & Supply Officer at Takeda.

Inauguration attended by Swiss and Japanese authorities

Takeda will inaugurate its new aseptic filling line in the presence of Swiss and Japanese institutional and political representatives, alongside Takeda employees. Federal Councilor Guy Parmelin, Head of the Federal Department of Economic Affairs, Education and Research (EAER), Florence Nater, State Councilor and Head of the Department of Economic Affairs and Social Cohesion (DECS), and H. E. Toshiro Iijima Ambassador-designate of Japan to Switzerland and Liechtenstein, will attend the event. All emphasize Takeda's importance at cantonal, federal, and international levels. This investment is part of a broader effort across Takeda's manufacturing network which will include also significant investments into US-based sites.

Takeda, a key player in biopharmaceutical innovation in Neuchâtel

For nearly 30 years, the Neuchâtel site has been dedicated to manufacturing medicines for patients with rare diseases, particularly bleeding disorders such as hemophilia. Operating 24/7, the site employs more than 650 people, making it one of the canton's ten largest



employers. Over 50 percent of the construction and engineering work for the new line was supported by local partners, further reinforcing the site's strong roots in the regional economy. Since 2024 a photovoltaic system with a capacity of 3.6 MW generating 25 percent of the site's total electricity needs demonstrates Takeda's commitment to reach net-zero greenhouse gas emissions in its operations by 2035.

You can find photos of the site and the official ceremony at the following link: <https://events-takeda.ch/en/#EC472B>

About Takeda

Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading value-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. We serve patients in approximately 80 countries and are driven by our purpose grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.

Media Contact :

Alexander Kandt

Global Manufacturing & Supply (GMS)

Head of Communications GMS

alexander.kandt@takeda.com

+ 41 79 893 42 26